Long-term investment opportunities can be hard to come by – especially if you don’t know what you should be looking for. But it’s even rarer to stumble across an opportunity that’s also life-changing. It’s a win-win scenario for everyone involved. On this episode of Making Money With Matt McCall, Matt dives into one such opportunity – the suddenly booming market for obesity drugs.
This trend has been in the news a lot lately. And it could be a game-changer for a wide variety of people. So Matt discusses some of the most prominent players in the space. And he highlights some smaller companies you may not be familiar with that are also working on related drugs. This is a must-watch show – whether you’re simply invested in the stock market or interested in learning about what could be the most significant breakthrough in medicine in decades.
#medicine #weightloss #investing #stockmarket
00:00 – Obesity to Have the Biggest Breakthrough in Medicine
4:36 42% of Americans are Living with Obesity
6:37 Global Economic Impact of Obesity Will Reach $4.32 Trillion
10:30 Celebrity and Social Influence of Weight Loss Drugs
12:24 New Developments in Weight Loss Drugs
16:51 Novo Nordisk (NVO)
17:40 Obesity Durg Market Potential Breakouts
21:47 Eli Lilly Releases New Obesity Drug, Mounjaro
25:29 Pfizer Experimental Drug Developments
27:30 Viking Therapeutics (VKTX)
32:46 Structure Therapeutics (GPCR)
34:38 Zealand Pharma (ZLDPF)
➡️ Follow us on Facebook: https://www.facebook.com/StansberryResearch
➡️ Follow us on Twitter: https://twitter.com/stansberry
➡️ Follow us on Instagram: https://www.instagram.com/stansberry_research
➡️ Follow us on LinkedIn: https://www.linkedin.com/company/stanberry-research